Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct 8;400(10359):1175-1176.
doi: 10.1016/S0140-6736(22)01929-8.

Real-world effectiveness of oral antivirals for COVID-19

Charles Burdet  1 , Florence Ader  2
Affiliations
Comment

Real-world effectiveness of oral antivirals for COVID-19

Charles Burdet et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

CB reports consulting fees from Da Volterra and Mylan and from 4Living Biotech (member of a data safety monitoring board for a clinical trial [LEONARDO] to investigate the effect of plerixafor in acute respiratory failure related to COVID-19), which are all unrelated to the topic of this Comment. FA declares no competing interests.

Comment on

References

    1. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–520. - PMC - PubMed
    1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397–1408. - PMC - PubMed
    1. Wong CKH, Au ICH, Lau TKK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400:1213–1222. - PMC - PubMed
    1. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients. Clin Infect Dis. 2022 doi: 10.1093/cid/ciac443. published online June 2. - DOI - PMC - PubMed
    1. Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. Antiviral Res. 2022;198 - PMC - PubMed